This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
15 December 2016, Merck Sharp & Dohme (New Zealand) Ltd (MSD) today announced ZEPATIER® (elbasvir/grazoprevir) has been registered by Medsafe for the treatment of chronic Hepatitis C – genotype 1, 3* and 4 infection in adults.
MSD New Zealand Director, Mr Paul Smith, adds, “Although ZEPATIER is now registered, it is not yet funded by PHARMAC. We will continue to work with PHARMAC in order to provide access to ZEPATIER for all appropriate G1, G3 and G4 patients living with HCV.”
* G3 treatment (only in combination with sofosbuvir)
Read more…http://www.scoop.co.nz/stories/GE1612/S00075/new-medicine-to-fight-hepatitis-c-now-registered.htm